
-
Eiger BioPharmaceuticals NasdaqGM:EIGR Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Location: 2155 Park Boulevard, Palo Alto, CA, 94306, United States | Website: https://www.eigerbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.88M
Cash
44.43M
Avg Qtr Burn
-20.71M
Short % of Float
2.64%
Insider Ownership
11.80%
Institutional Own.
43.86%
Qtr Updated
09/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zokinvy™ (lonafarnib) Details Progeroid laminopathies, Progeria, Hutchinson-Gilford progeria syndrome | Approved Quarterly sales | |
Lonafarnib Details Liver disease, Infectious disease, Hepatitis D | Phase 3 Update | |
Avexitide (GLP-1 Antagonist) Details Metabolic disorder, Congenital Hyperinsulinism | Phase 3 Update | |
Avexitide (GLP-1 Antagonist) Details Post-Bariatric Hypoglycemia, Metabolic disorder, Rare diseases | Phase 3 Update | |
Peginterferon Lambda + Lonafarnib Details Infectious disease, Hepatitis D | Phase 2 Update | |
Peginterferon Lambda (Lambda) Details Infectious disease, Hepatitis D | Failed Discontinued | |
Failed Discontinued |